PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy - Dermani, Fatemeh K.; Samadi, Pouria; Rahmani, Golebagh; Kohlan, Alisa K.; Najafi, Rezvan (Journal of cellular physiology, 2019)
Keywords: Animals; Anticancer properties; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antitumor activity; Apoptosis; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; Cancer; Cancer therapies; Cell death; Dendritic cells; Humans; Immune checkpoint; immune checkpoints; Immunity; Immunotherapy - adverse effects; Immunotherapy - methods; Ligands; Lymphocytes; Lymphocytes B; Lymphocytes T; Molecular Targeted Therapy; Natural killer cells; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - pathology; PD-L1 protein; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Programmed Cell Death 1 Receptor - metabolism; programmed cell death protein 1 (PD‐1); programmed death ligand 1 (PD‐L1); Proteins; Signal Transduction; Treatment Outcome; Tumor cells; Tumor Escape; Tumor Microenvironment; Tumors; cancer; programmed death ligand 1 (PD-L1); programmed cell death protein 1 (PD-1); immune checkpoints